News Releases

Biogen to Present at the Evercore ISI HealthConX

November 26, 2018 at 4:05 PM EST

Cambridge, MA, - - Biogen Inc. (Nasdaq:BIIB) announced today that it will present at the Evercore ISI HealthConX. The webcast will be live on Wednesday, November 28, 2018 at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at http://investors.biogen.com/. An archived version of the webcast will be available following the presentation.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. 

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

  
Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442